177Lu-DOTA-rosopatamb

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug Name177Lu-DOTA-rosopatamb

Drug Alias Name177Lu-DOTA-rosopatamab177Lu-HuJ591单抗177Lu-DOTA-TLX591-CHO177Lu-DOTA-TLX591-CHOTLX591

ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNew Zealand +[6]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesTelix Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals (Innovations) Pty Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A